

The original disclosure in Japanese was released on October 25, 2022 at 15:00 (GMT +8)

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



October 25, 2022

Company Takara Bio Inc. (Securities code: 4974;  
Prime Market)  
Headquarters Nojihigashi 7-4-38, Kusatsu, Shiga, Japan  
Representative Koichi Nakao, President & CEO  
Contact Takuya Kakemi, Executive Officer, in charge  
of PR & IR Department  
Telephone (+81)77-565-6970  
Website <https://www.takara-bio.co.jp/>

## Notice Concerning Revisions to the First Half Financial Results Forecasts

Takara Bio Inc. hereby announces that in the light of the most recent operating trends, to revise the first half of the financial results forecasts for the fiscal year ending March 31, 2023 (April 1, 2022 – March 31, 2023), disclosed on May 12, 2022, as described below.

### 1. Revisions to financial results forecasts

Revisions to consolidated financial results forecasts for the first half of the current fiscal year (April 1, 2022 through September 30, 2022)

	Consolidated net sales	Consolidated operating profit	Consolidated ordinary profit	Net income attributable to owners of the parent	Net income per share
	Million yen	Million yen	Million yen	Million yen	Yen
Previously announced forecasts (A)	27,744	8,641	8,726	6,354	52.77
Revised forecasts (B)	32,500	10,800	10,900	8,500	70.59
Change (B-A)	4,755	2,158	2,173	2,145	-
Change (%)	17.1	25.0	24.9	33.8	-
(Reference) Actual consolidated results for the first half of the previous fiscal year (Fiscal year ended March 31, 2022)	31,551	14,105	14,241	10,009	83.12

The original disclosure in Japanese was released on October 25, 2022 at 15:00 (GMT +8)

## **2. Reason for revision**

Due to the impact of the new coronavirus 7th wave, sales of related testing products are expected to exceed the previously announced forecasts. As other businesses are generally expected to perform in line with expectations, net sales, operating profit, ordinary profit, and net income attributable to owners of the parent are expected to exceed the previously announced forecasts. Therefore, the forecasts of consolidated financial results for the first half of the current fiscal year have been revised.

After further scrutiny, we plan to release our full-year consolidated results forecasts at the time of the announcement of our financial results for the first half on November 10, 2022.

---

### Forward-Looking Statements

Statements contained in these materials with respect to the Company's current plans, forecasts, strategies and beliefs that are not historical facts are forward-looking statements about the further performance of the Company and its consolidated subsidiaries. These statements are based on management's assumptions and beliefs in light of information currently available to it, but are based on a number of assumptions and beliefs derived from information that contains significant risks and uncertainties. Actual results may differ materially from these forecasts due to various factors. Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of our intellectual property rights, rapid advances in technology, and unfavorable verdicts in major litigation.